Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Warfarin versus aspirin in reduced ejection fraction
2004-002181-38Phase 3Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Aug 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in left ventricular systolic dysfunction (LVSD) and heart failure with reduced ejection fraction (HFrEF) comparing Warfarin arm with Aspirin arm (2 arms). Primary endpoint: Primary composite endpoint. Started Aug 2004; status: completed.
02
Drugs
warfarinaspirin
03
Conditions
left ventricular systolic dysfunction (LVSD)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2004-002181-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002181-38.